| Literature DB >> 11886382 |
Takemi Otsuki1, Kenichiro Yata, Haruko Sakaguchi, Junichi Kurebayashi, Yoshinobu Matsuo, Masako Uno, Tomohiro Fujii, Sakura Eda, Yumika Isozaki, Yoshihito Yawata, Osamu Yamada, Hideho Wada, Takashi Sugihara, Ayako Ueki.
Abstract
Recently, it was disclosed that all-trans retinoic acid (ATRA) inhibits myeloma cell growth by downregulating the interleukin 6 (IL-6)/IL-6 receptor (IL-6R) auto/paracrine loop, and upregulating p21/Cip1 cyclin-dependent kinase inhibitor (CDK-I), thereby inducing apoptosis with a decrease in Bcl-2 protein expression. To elucidate and generalize the effects of ATRA on the proliferation and cellular biology of myeloma cells, 12 human myeloma cell lines established in our laboratory were utilized. Two out of the 12 lines showed enhanced growth on supplementation of ATRA and were characterized by IL-10 production, downregulation of membrane Fas and reduced upregulation of p21/Cip1 CDK-I message. These characteristics may prove important for the clinical use of ATRA and should be considered before starting ATRA therapy for myeloma.Entities:
Mesh：
Substances：
Year: 2002 PMID： 11886382 DOI： 10.1046/j.0007-1048.2002.03336.x
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998